#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).
pharmaphorum.com/news/wnt-dru...
pharmaphorum.com/news/wnt-dru...
Wnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
pharmaphorum.com
September 25, 2026 at 9:22 AM
#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).
pharmaphorum.com/news/wnt-dru...
pharmaphorum.com/news/wnt-dru...
Merck reported that remigromig (MK-3000), its Wnt-pathway antibody acquired via the 2024 EyeBio buyout, met the non-inferiority primary endpoint versus ranibizumab in the Phase…
$MRK $SRZN $REGN named in the read, sent 11:42:00 AM ET. One of 37 alerts today.
knowfir.st
$MRK $SRZN $REGN named in the read, sent 11:42:00 AM ET. One of 37 alerts today.
knowfir.st
September 24, 2026 at 3:47 PM
Merck reported that remigromig (MK-3000), its Wnt-pathway antibody acquired via the 2024 EyeBio buyout, met the non-inferiority primary endpoint versus ranibizumab in the Phase…
$MRK $SRZN $REGN named in the read, sent 11:42:00 AM ET. One of 37 alerts today.
knowfir.st
$MRK $SRZN $REGN named in the read, sent 11:42:00 AM ET. One of 37 alerts today.
knowfir.st
Breaking: Merck is closing in on a $1.3 billion cash deal for closely held EyeBio. The deal would steer Merck, known for its cancer immunotherapy Keytruda, into the multibillion dollar eye-drug market.
www.wsj.com/health/pharm...
www.wsj.com/health/pharm...
May 29, 2024 at 1:19 AM
Breaking: Merck is closing in on a $1.3 billion cash deal for closely held EyeBio. The deal would steer Merck, known for its cancer immunotherapy Keytruda, into the multibillion dollar eye-drug market.
www.wsj.com/health/pharm...
www.wsj.com/health/pharm...
'The deal for EyeBio, whose drugs under development treat common eye diseases, will come in the form of a $1.3bn upfront payment with a further $1.7bn dependent on certain milestones being achieved'
www.ft.com/content/3e67...
www.ft.com/content/3e67...
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
www.ft.com
May 30, 2024 at 7:52 AM
'The deal for EyeBio, whose drugs under development treat common eye diseases, will come in the form of a $1.3bn upfront payment with a further $1.7bn dependent on certain milestones being achieved'
www.ft.com/content/3e67...
www.ft.com/content/3e67...
Thrilled to have David Guyer join the @lifebiosciences.bsky.social board, maker of the first anti-VEGF eye drug, two successful biotech IPOs, the largest ever ex-US pharma deal, and sale of his latest company, EyeBio, for ~$3B to Merck in 2024. Midas touch 🙏✨🥇
www.lifebiosciences.com/life-bioscie...
www.lifebiosciences.com/life-bioscie...
Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors
Life Bio adds accomplished biotech leader to its Board as the company prepares for an early 2026 initiation of human trials BOSTON, November 3, 2025 – Life Biosciences (“Life Bio”), a biotechnology co...
www.lifebiosciences.com
November 4, 2025 at 5:27 AM
Thrilled to have David Guyer join the @lifebiosciences.bsky.social board, maker of the first anti-VEGF eye drug, two successful biotech IPOs, the largest ever ex-US pharma deal, and sale of his latest company, EyeBio, for ~$3B to Merck in 2024. Midas touch 🙏✨🥇
www.lifebiosciences.com/life-bioscie...
www.lifebiosciences.com/life-bioscie...
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
https://www.ft.com/content/3e672f07-35ee-4ece-a8f6-88a52cbc9752
https://www.ft.com/content/3e672f07-35ee-4ece-a8f6-88a52cbc9752
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
US group hopes EyeBio will refill its pipeline with treatments targeting largest causes of blindness
www.ft.com
May 29, 2024 at 6:33 AM
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
https://www.ft.com/content/3e672f07-35ee-4ece-a8f6-88a52cbc9752
https://www.ft.com/content/3e672f07-35ee-4ece-a8f6-88a52cbc9752
MSD compra Verona Pharma por 8.553 millones de euros dozz.es/qmwi84
MSD compra Verona Pharma por 8.553 millones de euros
Ampliará su cartera para incluir Ohtuvayre (ensifentrina), un tratamiento de mantenimiento para la EPOC.
Más información: MSD vuelve al negocio de la oftalmología 10 años después con la compra de EyeBio por hasta 3.000 millones
dozz.es
July 9, 2025 at 12:28 PM
MSD compra Verona Pharma por 8.553 millones de euros dozz.es/qmwi84
MSD compra Verona Pharma por 8.553 millones de euros dozz.es/qmwi85
MSD compra Verona Pharma por 8.553 millones de euros
Ampliará su cartera para incluir Ohtuvayre (ensifentrina), un tratamiento de mantenimiento para la EPOC.
Más información: MSD vuelve al negocio de la oftalmología 10 años después con la compra de EyeBio por hasta 3.000 millones
dozz.es
July 9, 2025 at 12:35 PM
MSD compra Verona Pharma por 8.553 millones de euros dozz.es/qmwi85
Merck to buy EyeBio in $3 billion deal - Quartz: Merck to buy EyeBio in $3 billion deal Quartz https://news.google.com/rss/articles/CBMiK2h0dHBzOi8vcXouY29tL21lcmNrLWJ1eXMtZXllYmlvLTE4NTE1MDYyMzjSAQA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
May 29, 2024 at 3:17 PM
Merck to buy EyeBio in $3 billion deal - Quartz: Merck to buy EyeBio in $3 billion deal Quartz https://news.google.com/rss/articles/CBMiK2h0dHBzOi8vcXouY29tL21lcmNrLWJ1eXMtZXllYmlvLTE4NTE1MDYyMzjSAQA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
⚠️ MERCK TO ACQUIRE EYE DRUG COMPANY EYEBIO FOR UP TO $3 BILLION
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
May 29, 2024 at 11:02 AM
⚠️ MERCK TO ACQUIRE EYE DRUG COMPANY EYEBIO FOR UP TO $3 BILLION
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
⚠️ MERCK NEARS $1.3 BILLION CASH DEAL FOR EYE-DRUG COMPANY EYEBIO, WSJ REPORTS
Full Story → https://PiQSuite.com/reuters/merck-nears-13-billion-cash-deal-for-eye-drug-company-eyebio-wsj-reports
Full Story → https://PiQSuite.com/reuters/merck-nears-13-billion-cash-deal-for-eye-drug-company-eyebio-wsj-reports
May 29, 2024 at 1:26 AM
⚠️ MERCK NEARS $1.3 BILLION CASH DEAL FOR EYE-DRUG COMPANY EYEBIO, WSJ REPORTS
Full Story → https://PiQSuite.com/reuters/merck-nears-13-billion-cash-deal-for-eye-drug-company-eyebio-wsj-reports
Full Story → https://PiQSuite.com/reuters/merck-nears-13-billion-cash-deal-for-eye-drug-company-eyebio-wsj-reports
⚠️ MERCK TO ACQUIRE EYE DRUG COMPANY EYEBIO FOR UP TO $3 BILLION
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
May 29, 2024 at 11:02 AM
⚠️ MERCK TO ACQUIRE EYE DRUG COMPANY EYEBIO FOR UP TO $3 BILLION
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
Full Story → https://PiQSuite.com/reuters/merck-to-acquire-eye-drug-company-eyebio-for-up-to-3-billion
Ophthopedia Update: First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases: ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at Eyecelerator@AAO.
Restoret (MK-3000) is an…
Restoret (MK-3000) is an…
First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases
ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at Eyecelerator@AAO.
Restoret (MK-3000) is an antibody that activates Wnt in the retinal vasculature, Anthony P. Adamis, MD, chief scientific officer and cofounder of EyeBio, told Healio.
“Wnt is necessary for both the development and the maintenance of the blood-retinal barrier, and the hope was that by agonizing this pathway, we would get rid of excess fluid in diseases like diabetic macular edema,” he said.
In a phase 1b/2a clinical trial that
dlvr.it
October 17, 2025 at 5:13 PM
Ophthopedia Update: First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases: ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at Eyecelerator@AAO.
Restoret (MK-3000) is an…
Restoret (MK-3000) is an…
Ophthopedia Update: First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases: ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at… #ophthalmology #eye #eyenews
First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases
ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at Eyecelerator@AAO.
Restoret (MK-3000) is an antibody that activates Wnt in the retinal vasculature, Anthony P. Adamis, MD, chief scientific officer and cofounder of EyeBio, told Healio.
“Wnt is necessary for both the development and the maintenance of the blood-retinal barrier, and the hope was that by agonizing this pathway, we would get rid of excess fluid in diseases like diabetic macular edema,” he said.
In a phase 1b/2a clinical trial that
dlvr.it
October 17, 2025 at 5:09 PM
Ophthopedia Update: First-in-class molecules may reduce fluid, improve visual acuity in retinal diseases: ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at… #ophthalmology #eye #eyenews
@Reuters: Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports https://t.co/miW1TJHgKE https://t.co/Cs1txs4sOj
May 29, 2024 at 3:25 AM
@Reuters: Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports https://t.co/miW1TJHgKE https://t.co/Cs1txs4sOj